Mode
Text Size
Log in / Sign up

64 Cu-PSMA-617 shows highest detection rates in biochemically recurrent prostate cancerPSMA PET scans find prostate cancer better than older tests

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that 64 Cu-PSMA-617 may have the highest detection rates in biochemically recurrent prostate cancer, but evidence is uncertain.

This is a systematic review and network meta-analysis of PSMA-directed PET tracers for prostate cancer, including 68 Ga-PSMA-11, 64 Cu-PSMA-617, 18 F-DCFPyL, and 18 F-PSMA-1007. The analysis compared detection rates against non-PSMA tracers in patients with primary and biochemically recurrent prostate cancer, with a total sample of 1681 patients (1681 for biochemical recurrence, 271 for primary PC, with 2 overlapping). The authors synthesized that PSMA-directed tracers achieved higher detection rates than non-PSMA probes, with relative risks reported but absolute numbers not reported. Among PSMA tracers in biochemically recurrent disease, 64 Cu-PSMA-617 achieved the highest estimated detection rate, followed by 18 F-DCFPyL, 18 F-PSMA-1007, and 68 Ga-PSMA-11. In primary prostate cancer, both 18 F-PSMA-1007 and 18 F-DCFPyL showed higher detection rates than 68 Ga-PSMA-11. The authors acknowledge some uncertainty remained for reference standards and timing. Safety data were not reported. The practice relevance suggests that when available, 18 F-labeled PSMA tracers should be preferred, though the evidence is not definitive.

A review of many studies compared different PET scans for finding prostate cancer. The scans use special tracers to light up cancer cells. The main goal was to see how well each scan found cancer in patients whose PSA levels rose after treatment.

The results showed that PSMA PET scans were better than older, non-PSMA scans. Among the PSMA scans, 64 Cu-PSMA-617 found the most cancers, followed by 18 F-DCFPyL, 18 F-PSMA-1007, and 68 Ga-PSMA-11. For patients with newly diagnosed prostate cancer, 18 F-PSMA-1007 and 18 F-DCFPyL were better than 68 Ga-PSMA-11.

The review included over 1,600 patients, mostly with recurrent prostate cancer. It did not report safety data or how long patients were followed. Some uncertainty remains about the best standards for comparison.

When available, doctors should prefer 18 F-labeled PSMA tracers. These scans can help find prostate cancer more accurately, which may lead to better treatment decisions.

What this means for you:
PSMA PET scans, especially 64 Cu-PSMA-617, find prostate cancer more often than older tests.

Study Details

Study typeMeta analysis
Sample sizen = 1,681
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) tracers have reshaped prostate cancer (PC) imaging, supplementing non-PSMA options such as choline-based agents. However, direct comparative performance data across tracers remain scarce, leaving the optimal choice uncertain. We therefore conducted a systematic review and network meta-analysis (NMA) to assess detection rates (DRs) among PET tracers used for primary and biochemically recurrent PC. METHODS: Following PRISMA-NMA guidelines, we systematically searched PubMed, Embase, Cochrane Library, and ClinicalTrials.gov through March 2025 for studies comparing 2 PET tracers for prostate cancer. The primary outcome was DR, defined as the proportion of PET-positive patients or lesions. Two reviewers independently extracted data on study design, patient demographics, and imaging parameters, and evaluated quality with QUADAS-2. We performed frequentist random-effects NMA to calculate relative risks (RRs) with 95% CIs, using 68 Ga-PSMA-11 as reference. RESULTS: Nineteen studies (1681 patients) addressed biochemical recurrence, and 6 (271 patients) targeted primary PC, with 2 overlapping. Risk of bias was low for most domains, though some uncertainty remained for reference standards and timing. In biochemically recurrent PC, PSMA-directed tracers achieved higher DRs than non-PSMA probes. Within the PSMA tracers, 64 Cu-PSMA-617 achieved the highest estimated DR, followed by 18 F-DCFPyL, 18 F-PSMA-1007, and 68 Ga-PSMA-11. Both 18 F-PSMA-1007 and 18 F-DCFPyL showed higher DRs than 68 Ga-PSMA-11 in primary and recurrent PC. CONCLUSIONS: PSMA tracers outperform non-PSMA alternatives for detecting biochemical recurrence. Among PSMA tracers, 18 F-labeled agents consistently surpass 68 Ga-PSMA-11 in both biochemically recurrent and primary PC. When available, 18 F-labeled PSMA tracers should be preferred.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.